top of page
The Professional Network for Healthcare Experts
IntraGel and UroGen sign oncology collaboration with $7 million investment and global licensing options
The agreements give UroGen access to IntraGel's sustained-release drug delivery platform while supporting development of the Phase II-ready cancer therapy TumoCure through an equity investment and future licensing options.
nuaxia
Aug 213 min read
FDA accepts UroGen’s UGN-103 NDA for recurrent low-grade intermediate-risk bladder cancer
The submission seeks approval for a next-generation mitomycin formulation designed for intravesical treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, building on the same drug-delivery platform as FDA-approved Zusduri.
nuaxia
Aug 182 min read
bottom of page